Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vaccine Safety Body Proposed To Remove FDA “Conflict Of Interest”

Executive Summary

A proposal to move postmarket vaccine safety monitoring to an independent board outside FDA and CDC will be considered by the National Vaccine Advisory Committee at its next meeting

You may also be interested in...



IoM finds no thimerosal link to autism

Neither the measles-mumps-rubella vaccine nor thimerosal-containing vaccines are associated with autism, a May 17 Institute of Medicine report says. The 1report, "Immunization Safety Review: Vaccines and Autism," updates a 2001 report that found the link between thimerosal and neurodevelopmental disorders was unclear (2"The Pink Sheet" Oct. 8, 2001, p. 11). The latest report is based on "overwhelming evidence from several well-designed" clinical and epidemiological studies...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Latest Headlines
See All
UsernamePublicRestriction

Register

PS044134

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel